AroCell is a Swedish diagnostics company focused on enhancing the monitoring of oncological and bacterial diseases through innovative in vitro diagnostic (IVD) tests. One of their key products is the UBC® Rapid test, designed for the rapid detection and monitoring of bladder cancer at the point-of-care. This test provides healthcare professionals with valuable information to aid in the diagnosis of bladder cancer. Additionally, AroCell offers the TUBEX® TF test, which is a sensitive and rapid diagnostic tool for detecting acute typhoid fever caused by Salmonella typhi, further showcasing their commitment to addressing critical health issues.

Another significant technology from AroCell is the TK 210 ELISA kit, which serves as a biomarker for cell proliferation in various cancers, including hematological malignancies and solid tumors such as breast, prostate, and ovarian cancers. This quantitative immunoassay measures the concentration of Thymidine Kinase 1 (TK1) in blood samples, providing insights into tumor activity and therapy response. The TK 210 ELISA kit is designed to be user-friendly and can be integrated into standard laboratory processes, making it a valuable tool for clinicians in optimizing cancer treatment and monitoring patient outcomes.

Sweden

AroCell AB is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser. 


AroCell

Company Details